Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers
Abstract
Vedolizumab (VDZ) (previous versions MLN0002, MLN02, LDP-02) is a gut-selective integrin antagonist in phase 3 development for treatment of ulcerative colitis (UC) and Crohn's disease (CD). VDZ binds to the GI-homing integrin α4β7, antagonizing its interaction with MAdCAM-1 and thereby preventing migration of memory T lymphocytes into the GI tract. Natalizumab (NTZ), an integrin antagonist that binds to 2 integrins, α4β7 and α4β1, is approved...
Paper Details
Title
Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers
Published Date
Dec 1, 2011
Journal
Volume
17
Pages
S54 - S54
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History